QLS-111

QLS-111 · Qlaris Bio, Inc.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for QLS-111, covering 2025-01-20 to 2026-04-03. Get the full timeline:

Most recent: Clinical Trial Update: Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) [Phase 2]

See pricing